TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Message from the CEO to MediciNova Shareholders

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Yuichi Iwaki, M.D., Ph.D.
Message from the CEO to MediciNova Shareholders

MediciNova published research demonstrating how its drug MN-001 potentially improves cholesterol transport and addresses metabolic disorders, with Phase 2 trial results expected in summer 2026.

Insights
MNOV   positive

Company reported promising research findings, completed patient enrollment in Phase 2 trial, and demonstrated potential for novel therapeutic approach in treating metabolic and cardiovascular diseases